Search - tctmd.com

Displaying 221 - 240 of 548

$Hierarchical composite endpoints for heart failure trials - answering the question: What fraction of the composite endpoint is due to cardiovascular mortality, hospitalization, or quality of life?$

Presentation THT 2023

Hierarchical composite endpoints for heart failure trials - answering the question: What fraction of the composite endpoint is due to cardiovascular mortality, hospitalization, or quality of life?

Presenter: Michael Sutherland

March 21, 2023

Presentation THT 2023

Cardiovascular Hospitalization Rates in ATTR-CA: What Factors Make a Difference

Presenter: Margaret Cuomo

March 21, 2023

News Conference News THT 2023

TEER or VAD/Transplant in the Advanced HF Patient With MR?

Shelley Wood

March 20, 2023

News Conference News THT 2023

PCI’s Role for Patients With HFrEF and Extensive CAD: Experts Debate

Todd Neale

March 20, 2023

Presentation THT 2023

What are the Strengths and Limitations of a Two-Phase (6-Month Intermediate Endpoints & 12-18 Month Mortality and Heart Failure Hospitalization) Trial Design

Presenter: William Abraham

March 20, 2023

News Conference News ACC 2023

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

L.A. McKeown

March 14, 2023

News Conference News ACC 2023

Real-world Primary MR TEER Outcomes Carry a Reminder: Do Better

Shelley Wood

March 10, 2023

News Conference News ACC 2023

Wearable Device Helps HF Patients Avoid Coming Back to the Hospital: BMAD

Caitlin E. Cox

March 06, 2023

News Conference News ACC 2023

Too Many HF Patients Exiting Rural Hospitals Miss Out on Endorsed Therapies

Caitlin E. Cox

February 23, 2023

News Daily News

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

L.A. McKeown

February 17, 2023

News Daily News

Acute Cardiac Events More Common in COVID-19 Patients With Heart Histories

Caitlin E. Cox

February 10, 2023

News Daily News

Vast Majority of HFrEF Patients Eligible for Vericiguat

L.A. McKeown

February 08, 2023

News Daily News

Sepsis Emerges as Powerful CVD Risk Factor in Large US Analysis

L.A. McKeown

February 02, 2023

News Daily News

CRT Likely Benefits Broader Group of Patients: Meta-analysis

Todd Neale

February 01, 2023

News Daily News

More Hints That Cardiac Abnormalities Resolve Fully After MIS-C

Shelley Wood

January 16, 2023

News Daily News

Even When Eligible, Not All Acute HF Patients Get GDMT

Todd Neale

January 11, 2023

News Daily News

Cardiogenic Shock Outcomes Markedly Worse in De Novo HF Patients

Caitlin E. Cox

December 09, 2022

News Daily News

Query Use of Nontraditional Therapies for HF at Every Visit: AHA Statement

Todd Neale

December 09, 2022

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Daily News

Sequencing HF Meds? Most Doctors Stick to Old Habits, Survey Says

Todd Neale

December 08, 2022

Advertisement

Hierarchical composite endpoints for heart failure trials - answering the question: What fraction of the composite endpoint is due to cardiovascular mortality, hospitalization, or quality of life?

Cardiovascular Hospitalization Rates in ATTR-CA: What Factors Make a Difference

TEER or VAD/Transplant in the Advanced HF Patient With MR?

PCI’s Role for Patients With HFrEF and Extensive CAD: Experts Debate

What are the Strengths and Limitations of a Two-Phase (6-Month Intermediate Endpoints & 12-18 Month Mortality and Heart Failure Hospitalization) Trial Design

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

Real-world Primary MR TEER Outcomes Carry a Reminder: Do Better

Wearable Device Helps HF Patients Avoid Coming Back to the Hospital: BMAD

Too Many HF Patients Exiting Rural Hospitals Miss Out on Endorsed Therapies

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

Acute Cardiac Events More Common in COVID-19 Patients With Heart Histories

Vast Majority of HFrEF Patients Eligible for Vericiguat

Sepsis Emerges as Powerful CVD Risk Factor in Large US Analysis

CRT Likely Benefits Broader Group of Patients: Meta-analysis

More Hints That Cardiac Abnormalities Resolve Fully After MIS-C

Even When Eligible, Not All Acute HF Patients Get GDMT

Cardiogenic Shock Outcomes Markedly Worse in De Novo HF Patients

Query Use of Nontraditional Therapies for HF at Every Visit: AHA Statement

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Sequencing HF Meds? Most Doctors Stick to Old Habits, Survey Says

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content